BLA 020522 · Genentech
Nutropin Aq Pen
Somatropin · Injection
OrphanLast checked: Nov 19, 2026Latest source record: Jul 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Dec 29, 1995
Approved uses
7
Original approval plus efficacy supplements
Registered trials
540
176 Phase 3, 31 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 18, 2005 Supplement 27 · Efficacy LetterLabel
- Jun 28, 2005 Supplement 21 · Efficacy LetterLabelLabel
- Apr 13, 2000 Supplement 13 · Efficacy ReviewLabelLetter
- Dec 1, 1999 Supplement 9 · Efficacy ReviewLetter
- Dec 17, 1997 Supplement 4 · Efficacy Review
- Mar 24, 1997 Supplement 2 · Efficacy Review
- Dec 29, 1995 Original approval · Type 3 - New Dosage Form
6 products under this application
- NUTROPIN AQ PEN · SOMATROPIN 20MG/2ML (10MG/ML) · INJECTABLE, INJECTION · Discontinued
- NUTROPIN AQ NUSPIN · SOMATROPIN 20MG/2ML (10MG/ML) · INJECTABLE, INJECTION · Prescription
- NUTROPIN AQ PEN · SOMATROPIN 10MG/2ML (5MG/ML) · INJECTABLE, INJECTION · Discontinued
- NUTROPIN AQ NUSPIN · SOMATROPIN 10MG/2ML (5MG/ML) · INJECTABLE, INJECTION · Prescription
- NUTROPIN AQ NUSPIN · SOMATROPIN 5MG/2ML (2.5MG/ML) · INJECTABLE, INJECTION · Prescription
- NUTROPIN AQ · SOMATROPIN 10MG/2ML (5MG/ML) · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Somatropin" as an intervention, any sponsor and status, largest first.
- Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in ChildrenStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT03290235 · 1,500 participants (planned) · Start Mar 1, 2017 · Primary completion Oct 2020
Drug: PEG-somatropin · For: Growth Retardation
Sites: Wuhan, China
- Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and RehabilitationPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675714 · 1,126 participants · Start Jan 2004 · Primary completion Sep 2018
Drug: Humatrope; Ketoconazole and 5 more · For: Burns
Sites: Galveston, Texas
- Current Status of Islet Alpha Cell Function in Patients with Type 2 DiabetesPivotal-lookingRecruiting
Nanjing First Hospital, Nanjing Medical UniversityAcademic, hospital or other
NCT06825182 · 1,000 participants (planned) · Start Nov 7, 2024 · Primary completion Aug 1, 2025
Drug: Outpatient newly diagnosed type 2 diabetes subjects; Inpatient newly diagnosed type 2 diabetes subjects · For: Type 2 Diabetes Mellitus
Sites: Nanjing, China
- Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone DeficiencyStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT03249480 · 900 participants (planned) · Start Jan 2015 · Primary completion Aug 2017
Drug: PEG-somatropin · For: Growth Hormone Deficiency
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 28 sites in all
- Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency ChildrenStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT02314676 · 900 participants (planned) · Start Nov 2014 · Primary completion Jul 2017
Drug: PEG-somatropin · For: Dwarfism, Pituitary
Sites: Wuhu, China; Hangzhou, China
- Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone DeficiencyPivotal-lookingStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT02908958 · 900 participants (planned) · Start Nov 2014 · Primary completion Jun 2017
Drug: PEG-somatropin; PEG-somatropin · For: Growth Hormone Deficiency
Sites: Hefei, China; Wuhu, China; Xiamen, China · 22 sites in all
- The Effect of Somatropin Treatment in Adult Patients on Chronic DialysisPivotal-lookingTerminated
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00503698 · 712 participants · Start Jul 2007 · Primary completion Dec 2008
Drug: somatropin; placebo · For: Chronic Kidney Disease; End-Stage Renal Disease
Sites: Alexander City, Alabama; Birmingham, Alabama; Madison, Alabama · 381 sites in all
- Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort StudyPivotal-lookingCompleted
ShangHai Ji Ai Genetics & IVF InstituteAcademic, hospital or other
NCT05574894 · 692 participants · Start Jan 1, 2021 · Primary completion Jun 30, 2022
Drug: Growth hormone; GnRH antagonist · For: Growth Hormone; Advanced Maternal Age; PGT-A
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nutropin Aq Nuspin (Somatropin)
2024 spending
$3.9M
Beneficiaries
226
1,340 claims
Per beneficiary
$17,398
$593.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,670,920 |
| 2021 | $5,129,401 |
| 2022 | $4,648,208 |
| 2023 | $5,651,874 |
| 2024 | $3,931,944 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.
Deal CL, Steelman J, Vlachopapadopoulou E, et al. · J Clin Endocrinol Metab 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency.
Kildemoes RJ, Hollensen C, Biller BMK, et al. · Eur J Endocrinol 2022 · Clinical Trial
- Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.
Thornton PS, Maniatis AK, Aghajanova E, et al. · J Clin Endocrinol Metab 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study.
Gomez R, Lamoureux R, Turner-Bowker DM, et al. · Front Endocrinol (Lausanne) 2023 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Systematic review of the clinical effectiveness of Genotropin (somatropin) in children with short stature.
Loftus J, Heatley R, Walsh C, et al. · J Pediatr Endocrinol Metab 2010 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy and safety of Valtropin in the treatment of short stature in girls with Turner's syndrome.
Peterkova V, Savoy C, Bezlepkina O, et al. · J Pediatr Endocrinol Metab 2004 · Clinical Trial, Clinical Trial, Phase III
Sponsor: Roche (Genentech) · Also marketed as Nutropin Aq Nuspin, Nutropin Aq
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.